PLASMA MMP-9 LEVELS AS THE FUTURE RISK OF CONVERSION TO DEMENTIA IN APOE4-POSITIVE MCI PATIENTS: INVESTIGATION BASED ON THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE DATABASE
K. Abe, Y. Chiba, K. Ide, A. Yoshimi, T. Asami, A. Suda, T. Odawara, A. Hishimoto
J Prev Alz Dis 2022;2(9):331-337
Background: Matrix metalloproteinase 9 (MMP-9) has been reported to be correlated with declines in hippocampal volume and cognitive function in ApoE4-positive MCI patients.
Objectives: The present study was aimed to investigate the effects of plasma matrix MMP-9 on the conversion risk between mild cognitive impairment (MCI) patients with and without ApoE4.
Design and setting: Retrospective observational study using the data extracted from the Alzheimer’s Disease Neuroimaging Initiative database.
Participants: We included 211 ApoE4-positive MCI subjects (ApoE4+ MCI) and 184 ApoE4-negative MCI subjects (ApoE4- MCI).
Measurements: We obtained demographic and data including plasma MMP-9 levels at baseline and longitudinal changes in Clinical Dementia Rating (CDR) up to 15 years. We compared conversion rates between ApoE4+ MCI and ApoE4- MCI by the Log-rank test and calculated the hazard ratio (HR) for covariates including age, sex, educational attainment, drinking and smoking histories, medications, and plasma MMP-9 levels using a multiple Cox regression analysis of ApoE4+ MCI and ApoE4- MCI.
Results: No significant differences were observed in baseline plasma MMP-9 levels between ApoE4+ MCI and ApoE4- MCI. High plasma MMP-9 levels increased the conversion risk significantly more than low plasma MMP-9 levels (HR, 2.46 [95% CI, 1.31-4.48]) and middle plasma MMP-9 levels (HR, 1.67 [95% CI, 1.04-2.65]) in ApoE4+ MCI, but not in ApoE4- MCI.
Conclusion: Plasma MMP-9 would be the risk of the future conversion to dementia in ApoE4+ MCI.
K. Abe ; Y. Chiba ; K. Ide ; A. Yoshimi ; T. Asami ; A. Suda ; T. Odawara ; A. Hishimoto (2022): Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer’s Disease Neuroimaging Initiative Database. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2022.19